Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Income towards Parent Company: 2014-2025

Historic Income towards Parent Company for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Income towards Parent Company fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
  • Per vTv Therapeutics' latest filing, its Income towards Parent Company stood at -$10.3 million for Q3 2025, which was down 40.18% from -$7.4 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Income towards Parent Company peaked at -$841,000 during Q2 2021, and registered a low of -$10.3 million during Q3 2025.
  • Moreover, its 3-year median value for Income towards Parent Company was -$6.2 million (2025), whereas its average is -$6.6 million.
  • Examining YoY changes over the last 5 years, vTv Therapeutics' Income towards Parent Company showed a top increase of 83.15% in 2021 and a maximum decrease of 690.11% in 2021.
  • vTv Therapeutics' Income towards Parent Company (Quarterly) stood at -$9.5 million in 2021, then surged by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then slumped by 77.14% to -$10.3 million in 2025.
  • Its last three reported values are -$10.3 million in Q3 2025, -$7.4 million for Q2 2025, and -$6.2 million during Q1 2025.